Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction

Circulation

Volumn 95, Issue 12, 1997, Pages 2607-2609

  Oosterga, Margreeth ^a   Voors, Adriaan A ^b   De Kam, Pieter Jan ^b   Schunkert, Heribert ^b   Pinto, Yigal M ^b   Kingma, J Herre ^b   Van Gilst, Wiek H ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b NONE

Author keywords

Angiotensin; Enzymes; Genes; Myocardial infarction; Remodeling

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADAPTATION; ADULT; AGED; ARTICLE; DRUG BLOOD LEVEL; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; FEMALE; HEART DILATATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WOUND HEALING;

EID: 0030956056     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.12.2607     Document Type: Article

References (12)

1. White HD, Norris RM, Brown MA, Brandt PWT, Withlock RML, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44-51.
2. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation, 1990;81:1161-1172.
3. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE. Am J Hum Genet. 1992;51:197-205.
4. Pinto YM, van Gilst WH, Kingma JH, Schunkert H, for the CATS Investigators. The deletion-type allele of the angiotensin converting enzyme gene is associated with progressive ventricular dilatation after anterior myocardial infarction. J Am Coll Cardiol. 1995;25:1622-1626.
5. Kingma JH, van Gilst WH, Peels CH, Dambrink J-HE, Verheugt FWA, Wielenga RP, for the CATS Investigators. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Eur Heart J. 1994;13:898-907.
6. van der Laarse A, Kerkhof PLM, Vermeer F, Serruys PW, Hermens WT, Verheugt FW, Bar FW, Krans XH, van der Wall EE, Simoons ML. Relation between infarct size and left ventricular performance assessed in patients with first acute myocardial infarction randomized to intracoronary thrombolytic therapy or to conventional treatment. Am J Cardiol. 1988;61:1-7.
7. van Gilst WH, Kingma JH, Peels CH, Dambrink J-HE, St John-Sutton M, on behalf of the CATS Investigators. Which patient benefits from early angiotensin converting enzyme inhibition after myocardial infarction? J Am Coll Cardiol. 1996;28:114-121.
8. McAlpine HM, Morton JJ, Leckie B, Rumley A. Gillen G, Dargie HJ. Neuroendocrine activation after acute myocardial infarction. Br Heart J. 1988;60:117-124.
9. Sigurdsson A, Held P, Swedberg K. Short- and long-term neurohumoral activation following acute myocardial infarction. Am Heart J. 1993;126:1068-1076.
10. Nabel EG, Topol EJ, Galeana A, Ellis SG, Bates ER, Werns SW, Walton JA, Muller DW, Swaiger M, Pitt B. A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction. J Am Coll Cardiol. 1991;17:467-473.
11. Swedberg K. Neurohumoral activation is deleterious to the long term outcome in patients with congestive heart failure: protagonists' viewpoint. J Am Coll Cardiol. 1988;12:550-554.
12. Dzau VJ. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol. 1987;59:59A-65A.